news, journals and articles from all over the world.
Practice-changing research from Cedars-Sinai Cancer shows that a combination of androgen deprivation therapy—a commonly used hormone injection—plus pelvic lymph node radiation, kept nearly 90% of clinical trial patients’ prostate cancer at bay for five years. The findings were published in the peer-reviewed journal The Lancet.
Studies have shown that the way LGBTQ+ patients are screened, diagnosed and treated for cancer may put them at a significant disadvantage compared to cisgender heterosexual patients.
This tipsheet highlights the latest medical discoveries and faculty news at Cedars-Sinai. Links to full news releases are included with each item.
A hallmark of cancer is its ability to replicate, a process commonly driven by the reactivation of the telomerase enzyme complex, which helps prevent the aging and death of healthy cells and keeps stem cells in bone marrow and the intestines from producing normal cells in those organs. When telomerase is activated in cancer cells, it helps them survive and duplicate in the body.
Cedars-Sinai Cancer and Tempus, a leader in artificial intelligence and precision medicine, are harnessing the power of big data and AI to design personalized cancer treatment options by creating virtual replicas of patients’ DNA, RNA, protein and other information to help identify the most effective approach to each individual’s disease.
Two internationally prominent cancer experts from Cedars-Sinai and USC will train a new generation of investigators to propel scientific advances in cancer through a novel grant from the U.S. Department of Defense.
Researchers have discovered a new way to transform the tissues surrounding prostate tumors to help the body’s immune cells fight the cancer. The discovery, made in human and mouse cells and in laboratory mice, could lead to improvements in immunotherapy treatments for prostate cancer, the second most common cancer in men in the U.S.
Internationally prominent gynecologic oncologist Kenneth H. Kim, MD, recently was selected to direct the Division of Gynecologic Oncology at Cedars-Sinai Cancer. He also serves as chair of the cancer center’s Committee for Oversight of Training and Education.
A new approach to cancer therapy shows potential to transform the commonly used chemotherapy drug gemcitabine into a drug that kills cancer cells in a specialized way, activating immune cells to fight the cancer, according to a study led by Cedars-Sinai Cancer investigators.
Internationally recognized hematologist John P. Chute, MD, has been selected to direct the Division of Hematology and Cellular Therapy in the Department of Medicine at Cedars-Sinai Cancer. The physician-scientist also will serve as director of the Center for Myelodysplastic Diseases Research and associate director of the Board of Governors Regenerative Medicine Institute in the Department of Biomedical Sciences.
English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
Urdu